Richard Dillon

4.2k total citations
73 papers, 760 citations indexed

About

Richard Dillon is a scholar working on Hematology, Molecular Biology and Genetics. According to data from OpenAlex, Richard Dillon has authored 73 papers receiving a total of 760 indexed citations (citations by other indexed papers that have themselves been cited), including 58 papers in Hematology, 33 papers in Molecular Biology and 20 papers in Genetics. Recurrent topics in Richard Dillon's work include Acute Myeloid Leukemia Research (48 papers), Acute Lymphoblastic Leukemia research (16 papers) and Chronic Myeloid Leukemia Treatments (15 papers). Richard Dillon is often cited by papers focused on Acute Myeloid Leukemia Research (48 papers), Acute Lymphoblastic Leukemia research (16 papers) and Chronic Myeloid Leukemia Treatments (15 papers). Richard Dillon collaborates with scholars based in United Kingdom, United States and Australia. Richard Dillon's co-authors include Nigel H. Russell, Sylvie Freeman, Nicola Potter, Ian Thomas, Amanda Gilkes, Kavita Raj, Alan K. Burnett, David Grimwade, Claire Harrison and Manohursingh Runglall and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and Blood.

In The Last Decade

Richard Dillon

64 papers receiving 749 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Richard Dillon United Kingdom 15 531 227 174 150 116 73 760
Toshiro Kawakita Japan 11 319 0.6× 90 0.4× 91 0.5× 118 0.8× 75 0.6× 77 504
Ming-Chih Liu Taiwan 12 645 1.2× 410 1.8× 271 1.6× 106 0.7× 52 0.4× 17 883
Shaun Fleming Australia 14 412 0.8× 302 1.3× 117 0.7× 101 0.7× 219 1.9× 56 815
Kazuaki Yakushiji Japan 10 113 0.2× 67 0.3× 43 0.2× 41 0.3× 80 0.7× 18 387
Michaela Kotrová Germany 13 287 0.5× 172 0.8× 112 0.6× 312 2.1× 127 1.1× 31 666
Norimichi Hattori Japan 13 195 0.4× 112 0.5× 81 0.5× 43 0.3× 157 1.4× 66 534
MJ Willemse Netherlands 13 490 0.9× 90 0.4× 106 0.6× 569 3.8× 100 0.9× 13 805
Jess F. Peterson United States 15 228 0.4× 205 0.9× 113 0.6× 119 0.8× 101 0.9× 83 584
J Díaz-Mediavilla Spain 12 491 0.9× 320 1.4× 159 0.9× 189 1.3× 139 1.2× 22 771
Wandi Zhang United States 10 116 0.2× 177 0.8× 143 0.8× 76 0.5× 204 1.8× 26 668

Countries citing papers authored by Richard Dillon

Since Specialization
Citations

This map shows the geographic impact of Richard Dillon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Richard Dillon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Richard Dillon more than expected).

Fields of papers citing papers by Richard Dillon

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Richard Dillon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Richard Dillon. The network helps show where Richard Dillon may publish in the future.

Co-authorship network of co-authors of Richard Dillon

This figure shows the co-authorship network connecting the top 25 collaborators of Richard Dillon. A scholar is included among the top collaborators of Richard Dillon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Richard Dillon. Richard Dillon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Russell, Nigel H., Jad Othman, Oliver Cumming, et al.. (2025). Safety and efficacy of combining midostaurin and gemtuzumab ozogamicin with induction chemotherapy in FLT3 -mutated AML. Blood Advances. 9(24). 6455–6466.
2.
Dillon, Richard, et al.. (2025). Acute leukaemia. Medicine. 53(5). 288–297.
3.
Devonshire, Alison S., Richard Dillon, Christian Thiede, et al.. (2024). Recommendations from the AML molecular MRD expert advisory board. Leukemia. 38(7). 1638–1641. 2 indexed citations
4.
Tiong, Ing Soo, Devendra Hiwase, Ashish Bajel, et al.. (2024). Targeting Molecular Measurable Residual Disease and Low-Blast Relapse in AML With Venetoclax and Low-Dose Cytarabine: A Prospective Phase II Study (VALDAC). Journal of Clinical Oncology. 42(18). 2161–2173. 18 indexed citations
5.
Short, Nicholas J. & Richard Dillon. (2024). Measurable residual disease monitoring in AML: Prospects for therapeutic decision‐making and new drug development. American Journal of Hematology. 100(S2). 5–15. 5 indexed citations
6.
Othman, Jad, Nicola Potter, Adam Ivey, et al.. (2024). Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission. Blood. 143(19). 1931–1936. 33 indexed citations
7.
Loo, Sun, Nicola Potter, Adam Ivey, et al.. (2024). Pretransplant MRD detection of fusion transcripts is strongly prognostic in KMT2A-rearranged acute myeloid leukemia. Blood. 144(24). 2554–2557. 4 indexed citations
8.
Loke, Justin, Aimee Jackson, Shamyla Siddique, et al.. (2023). Posttransplant MRD and T-cell chimerism status predict outcomes in patients who received allografts for AML/MDS. Blood Advances. 7(14). 3666–3676. 21 indexed citations
9.
Ravandi, Farhad, Jacqueline Cloos, Francesco Buccisano, et al.. (2023). Measurable residual disease monitoring in patients with acute myeloid leukemia treated with lower‐intensity therapy: Roadmap from an ELN‐DAVID expert panel. American Journal of Hematology. 98(12). 1847–1855. 10 indexed citations
10.
Harrington, Patrick, Richard Dillon, Deepti Radia, et al.. (2022). Chronic myeloid leukaemia patients at diagnosis and resistant to tyrosine kinase inhibitor therapy display exhausted T‐cell phenotype. British Journal of Haematology. 198(6). 1011–1015. 8 indexed citations
11.
Loo, Sun, Richard Dillon, Adam Ivey, et al.. (2022). Pretransplant FLT3-ITD MRD assessed by high-sensitivity PCR-NGS determines posttransplant clinical outcome. Blood. 140(22). 2407–2411. 42 indexed citations
12.
Mehta, Priyanka, Nick Telford, Richard Dillon, et al.. (2022). Recommendations for laboratory testing of UK patients with acute myeloid leukaemia. British Journal of Haematology. 200(2). 150–159. 4 indexed citations
13.
Alimam, Samah, Richard Dillon, Michael A. Simpson, et al.. (2021). Patients with triple-negative, JAK2V617F- and CALR-mutated essential thrombocythemia share a unique gene expression signature. Blood Advances. 5(4). 1059–1068. 14 indexed citations
14.
Harrington, Patrick, Hugues de Lavallade, Katie J. Doores, et al.. (2021). Single dose of BNT162b2 mRNA vaccine against SARS-CoV-2 induces high frequency of neutralising antibody and polyfunctional T-cell responses in patients with myeloproliferative neoplasms. Leukemia. 35(12). 3573–3577. 31 indexed citations
15.
Harrington, Patrick, Claire Harrison, Richard Dillon, et al.. (2021). Evidence of robust memory T‐cell responses in patients with chronic myeloproliferative neoplasms following infection with severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2). British Journal of Haematology. 193(4). 692–696. 5 indexed citations
16.
Alimam, Samah, Claire Harrison, Richard Dillon, et al.. (2020). Altered immune response to the annual influenza A vaccine in patients with myeloproliferative neoplasms. British Journal of Haematology. 193(1). 150–154. 10 indexed citations
17.
Russell, Nigel H. & Richard Dillon. (2020). UK Experience of an Alternative ATO Dosing Regimen in APL. Frontiers in Oncology. 10. 594129–594129. 2 indexed citations
18.
Milne, Paul, Charlotte S. Wilhelm-Benartzi, Michael R. Grunwald, et al.. (2019). Serum Flt3 ligand is a biomarker of progenitor cell mass and prognosis in acute myeloid leukemia. Blood Advances. 3(20). 3052–3061. 17 indexed citations
19.
Cloos, Jacqueline, Gert J. Ossenkoppele, & Richard Dillon. (2019). Minimal residual disease and stem cell transplantation outcomes. Hematology. 2019(1). 617–625. 11 indexed citations
20.
Dillon, Richard & Claire Harrison. (2009). Full blood count. British Journal of Hospital Medicine. 70(Sup3). M38–M41. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Toshiro Kawakita Breakdown of academic impact, for papers by Ming-Chih Liu Breakdown of academic impact, for papers by Shaun Fleming Breakdown of academic impact, for papers by Kazuaki Yakushiji Breakdown of academic impact, for papers by Michaela Kotrová Breakdown of academic impact, for papers by Norimichi Hattori Breakdown of academic impact, for papers by MJ Willemse Breakdown of academic impact, for papers by Jess F. Peterson Breakdown of academic impact, for papers by J Díaz-Mediavilla Breakdown of academic impact, for papers by Wandi Zhang
Rankless by CCL
2026